Natacha Entz-Werle
Strasbourg, France
NCT Number: NCT00213876
At present, diagnosis of oligodendroglioma is made on histological and radiographic criteria in the French Mayo-Ste Anne classification. The less frequent grade A oligodendrogliomas are characterized by no vascular contrast on RMN evaluation comparatively to grade B forms. This benign histological subtype relapses in few cases with a more aggressive histology. To determine these relapsed cases at diagnosis, a collection of tumour begun in February 2004. Then, our study was designed to identify diagnostic molecular and metabolic markers that could eventually be used as a signature characterising grade A versus grade B oligodendrogliomas. The molecular analysis will use genomic techniques like allelotyping study, quantitative real-time PCR, gene sequencing , serial analysis of genomic expression and immunohistochemistry, since the metabolic study will be the spectroscopic examination of in vivo tumour. This study will include paediatric and adult patients followed for oligodendrogliomas, medulloblastomas and gliomas to compare the different tumour signatures. All these results will be correlated to survival and clinical features.
Looking for future studies?
Notify Me1 year and older
All sexes
Observational
Strasbourg, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
University Hospital, Strasbourg, France
Other
Research of Molecular and Metabolic Diagnostic Markers in Oligodendrogliomas A and B Comparatively.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03027388
Astrocytoma, Astrocytoma, Grades II, III and IV
Bethesda, Maryland, United States
View Trial DetailsNCT02388659
Astrocytoma, Astrocytomas
Dallas, Texas, United States
View Trial DetailsNCT02731521
Astrocytoma, Astrocytomas
Dallas, Texas, United States
View Trial DetailsNCT07673705
1p19q Codeletion, Astrocytoma
Mumbai, India
View Trial Details